Periodic Transaction Report | U.S. Office of Government Ethics; 5 C.F.R. part 2634

Executive Branch Personnel

Public Financial Disclosure Report:

Periodic Transaction Report (OGE Form 278-T)

Filer's Information

Price, Thomas

Secretary, Department of Health & Human Services

Electronic Signature - I certify that the statements I have made in this form are true, complete and correct to the best of my knowledge.

/s/ Price, Thomas [electronically signed on 03/10/2017 by Price, Thomas in Integrity.gov] - Filer received a 47 day filing extension.

Agency Ethics Official's Opinion - On the basis of information contained in this report, I conclude that the filer is in compliance with applicable laws and regulations (subject to any comments below).

/s/ Hall, Randall, Certifying Official [electronically signed on 03/21/2017 by Hall, Randall in Integrity.gov]

Other review conducted by

/s/ Hall, Randall, Ethics Official [electronically signed on 03/21/2017 by Hall, Randall in Integrity.gov]

U.S. Office of Government Ethics Certification

/s/ Skalla, Daniel L, Certifying Official [electronically signed on 03/30/2017 by Skalla, Daniel L in Integrity.gov]

Transactions

#	DESCRIPTION	ТҮРЕ	DATE	NOTIFICATION OVER 30 DAYS AGO	AMOUNT
1	Xerox Corp	Sale	02/15/17	No	\$1,001 - \$15,000

#	DESCRIPTION	ТҮРЕ	DATE	NOTIFICATION OVER 30 DAYS AGO	AMOUNT
2	Bristol-Myers Squibb	Sale	02/15/17	No	\$1,001 - \$15,000
3	athenahealth, Inc Common Stock	Sale	02/15/17	No	\$1,001 - \$15,000
4	L Brands Inc	Sale	02/15/17	No	\$1,001 - \$15,000
5	Kansas City Southern Inc	Sale	02/15/17	No	\$1,001 - \$15,000
6	Sempra Energy	Sale	02/15/17	No	\$1,001 - \$15,000
7	McKesson Corp	Sale	02/15/17	No	\$1,001 - \$15,000
8	Cognizant Technology Solutions Corporation - Class A Common Stock	Sale	02/15/17	No	\$1,001 - \$15,000
9	CVS Health Corp	Sale	02/15/17	No	\$1,001 - \$15,000
10	Verizon Communications Inc	Sale	02/15/17	No	\$1,001 - \$15,000
11	United Technologies Corp	Sale	02/10/17	No	\$1,001 - \$15,000
12	Pfizer Inc	Sale	02/10/17	No	\$1,001 - \$15,000
13	Northrop Grumman Corp	Sale	02/10/17	No	\$1,001 - \$15,000
14	Lilly Eli & Co	Sale	02/10/17	No	\$1,001 - \$15,000
15	Apple Inc.	Sale	02/10/17	No	\$15,001 - \$50,000
16	Amgen Inc	Sale	02/10/17	No	\$1,001 - \$15,000
17	HP Inc Com	Sale	02/10/17	No	\$1,001 - \$15,000
18	Whitewave foods corp cl A	Sale	02/10/17	No	\$1,001 - \$15,000
19	Crown Castle Intl Corp	Sale	02/10/17	No	\$1,001 - \$15,000
20	Calpine Corp New	Sale	02/10/17	No	\$1,001 - \$15,000
21	Arris Intl Inc	Sale	02/10/17	No	\$1,001 - \$15,000
22	Alphabet Inc Cl A	Sale	02/10/17	No	\$1,001 - \$15,000
23	LyondellBasell Industries N.V.	Sale	02/10/17	No	\$1,001 - \$15,000
24	American Tower Reit Com	Sale	02/10/17	No	\$1,001 - \$15,000

#	DESCRIPTION	ТҮРЕ	DATE	NOTIFICATION OVER 30 DAYS AGO	AMOUNT
25	CBS Corp B	Sale	02/10/17	No	\$1,001 - \$15,000
26	Biogen Idec Inc Common Stock	Sale	02/10/17	No	\$1,001 - \$15,000
27	Zimmer Biomet Hldgs Inc Com	Sale	02/10/17	No	\$1,001 - \$15,000
28	NextEra Energy Inc	Sale	02/10/17	No	\$1,001 - \$15,000
29	Aetna Inc	Sale	02/10/17	No	\$1,001 - \$15,000
30	Jazz Pharmaceuticals plc - Ordinary Shares	Sale	02/10/17	No	\$1,001 - \$15,000
31	Honeywell Intl Inc	Sale	02/10/17	No	\$1,001 - \$15,000
32	PG&E Corporation	Sale	02/10/17	No	\$1,001 - \$15,000
33	Delta Air Lines	Sale	02/10/17	No	\$1,001 - \$15,000
34	Starbucks Corp	Sale	02/10/17	No	\$1,001 - \$15,000
35	Innate Immunotherapeutics Ltd.	Sale	02/10/17	No	\$15,001 - \$50,000
36	Arch Capital Group Ltd Common Stock	Sale	02/15/17	No	\$1,001 - \$15,000
37	Innate Immunotherapeutics Ltd	Sale	02/10/17 and 2/13/17	No	\$250,001 - \$500,000

Endnotes

Summary of Contents

The 278-T discloses purchases, sales, or exchanges of securities in excess of \$1,000 made on behalf of the filer, the filer's spouse, or dependent child. Transactions are required to be disclosed within 30 days of receiving notification of a transaction but not later than 45 days after the transaction. Filers need not disclose (1) mutual funds and other excepted investment funds; (2) certificates of deposit, savings or checking accounts, and money market accounts; (3) U.S. Treasury bills, notes, and bonds; (4) Thrift Savings Plan accounts; (5) real property; and (6) transactions that are solely by and between the filer, the filer's spouse, and the filer's dependent children.

Privacy Act Statement

Title I of the Ethics in Government Act of 1978, as amended (the Act), 5 U.S.C. app. § 101 et seq., as amended by the Stop Trading on Congressional Knowledge Act of 2012 (Pub. L. 112-105) (STOCK Act), and 5 C.F.R. Part 2634 of the U. S. Office of Government Ethics regulations require the reporting of this information. The primary use of the information on this report is for review by Government officials to determine compliance with applicable Federal laws and regulations. This report may also be disclosed upon request to any requesting person in accordance with sections 105 and 402(b)(1) of the Act or as otherwise authorized by law. You may inspect applications for public access of your own form upon request. Additional disclosures of the information on this report may be made: (1) to any requesting person, subject to the limitation contained in section 208(d)(1) of title 18, any determination granting an exemption pursuant to sections 208(b)(1) and 208(b)(3) of title 18; (2) to a Federal, State, or local law enforcement agency if the disclosing agency becomes aware of violations or potential violations of law or regulation; (3) to another Federal agency, court or party in a court or Federal administrative proceeding when the Government is a party or in order to comply with a judge-issued subpoena; (4) to a source when necessary to obtain information relevant to a conflict of interest investigation or determination; (5) to the National Archives and Records Administration or the General Services Administration in records management inspections; (6) to the Office of Management and Budget during legislative coordination on private relief legislation; (7) to the Department of Justice or in certain legal proceedings when the disclosing agency, an employee of the disclosing agency, or the United States is a party to litigation or has an interest in the litigation and the use of such records is deemed relevant and necessary to the litigation; (8) to reviewing officials in a new office, department or agency when an employee transfers or is detailed from one covered position to another; (9) to a Member of Congress or a congressional office in response to an inquiry made on behalf of an individual who is the subject of the record; (10) to contractors and other non-Government employees working on a contract, service or assignment for the Federal Government when necessary to accomplish a function related to an OGE Government-wide system of records; and (11) on the OGE Website and to any person, department or agency, any written ethics agreement filed with OGE by an individual nominated by the President to a position requiring Senate confirmation. See also the OGE/GOVT-1 executive branch-wide Privacy Act system of records.